- Home
- ALVR
ALVR
AlloVir Inc.
as 02-21-2025 4:00pm EST
AlloVir Inc is a late clinical-stage cell therapy company. The company focuses on developing innovative allogeneic T-cell therapies to combat viral diseases. Their proprietary VST therapy platform enables the creation of off-the-shelf VSTs, addressing the urgent medical need for treating patients with limited viral disease treatment options. With a singular focus on research, development, and commercialization, the company's platform targets 11 devastating viruses, with posoleucel being the lead candidate addressing six viruses. Operating within one segment, the company is dedicated to preventing and treating severe viral-associated diseases through off-the-shelf VST therapies.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 48.8M | IPO Year: | 2020 |
| Target Price: | N/A | AVG Volume (30 days): | 22.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -20.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $7.96 - $24.15 | Next Earning Date: | 03-14-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of AlloVir Inc. (ALVR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Miller Edward | ALVR | General Counsel | Jan 23 '25 | Sell | $9.70 | 52 | $494.03 | 6,628 | |
| Sinha Vikas | ALVR | See Remarks | Jan 23 '25 | Sell | $9.70 | 129 | $1,225.86 | 49,445 | |
| Hagen Brett R | ALVR | Chief Accounting Officer | Jan 23 '25 | Sell | $9.70 | 36 | $342.28 | 2,932 | |
| Miller Edward | ALVR | General Counsel | Jan 10 '25 | Sell | $0.44 | 409 | $180.00 | 6,628 | |
| Sinha Vikas | ALVR | See Remarks | Jan 10 '25 | Sell | $0.44 | 979 | $430.86 | 49,445 | |
| Hagen Brett R | ALVR | Chief Accounting Officer | Jan 10 '25 | Sell | $0.44 | 332 | $146.11 | 2,932 |
Latest AlloVir Inc. News
ALVR Breaking Stock News: Dive into ALVR Ticker-Specific Updates for Smart Investing
Pharmaceutical Technology
3 months ago
AlloVir and Kalaris enter merger to advance retinal disease therapies
MT Newswires
3 months ago
Sector Update: Health Care Stocks Edge Higher Premarket Friday
MT Newswires
3 months ago
Sector Update: Health Care
BioPharma Dive
3 months ago
Kalaris to go public via reverse merger with AlloVir
MT Newswires
3 months ago
AlloVir Signs Merger with Kalaris Therapeutics
GlobeNewswire
3 months ago
AlloVir and Kalaris Therapeutics Announce Agreement for Transformational Merger to Create Company Focused on Diseases of the Retina
Simply Wall St.
4 months ago
Discovering Opportunities: AlloVir And 2 Other US Penny Stocks
GuruFocus.com
4 months ago
Octagon Capital Advisors LP Increases Stake in AlloVir Inc
Compare ALVR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALVR AlloVir Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.